Robert M. Day

2.9k total citations · 1 hit paper
32 papers, 2.1k citations indexed

About

Robert M. Day is a scholar working on Immunology, Pathology and Forensic Medicine and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Robert M. Day has authored 32 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Immunology, 7 papers in Pathology and Forensic Medicine and 7 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Robert M. Day's work include Psoriasis: Treatment and Pathogenesis (17 papers), Pharmaceutical studies and practices (7 papers) and Ophthalmology and Eye Disorders (6 papers). Robert M. Day is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (17 papers), Pharmaceutical studies and practices (7 papers) and Ophthalmology and Eye Disorders (6 papers). Robert M. Day collaborates with scholars based in United States, Canada and Germany. Robert M. Day's co-authors include Kim Papp, Richard G. Langley, Kristian Reich, Joana Gonçalves, Randall M. Stevens, Craig L. Leonardi, ChiaChi Hu, Kenneth B. Gordon, C.E.M. Griffiths and Neil J. Korman and has published in prestigious journals such as The Lancet, The Journal of Clinical Endocrinology & Metabolism and Ophthalmology.

In The Last Decade

Robert M. Day

31 papers receiving 2.0k citations

Hit Papers

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor,... 2015 2026 2018 2022 2015 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
    2015 483 citations Kim Papp, Kristian Reich et al. Journal of the American Academy of Dermatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert M. Day United States 20 1.4k 865 421 360 309 32 2.1k
Jennifer Clay Cather United States 25 1.8k 1.3× 1.3k 1.5× 476 1.1× 419 1.2× 366 1.2× 71 2.6k
Peter van de Kerkhof Netherlands 21 2.3k 1.6× 1.5k 1.8× 407 1.0× 473 1.3× 417 1.3× 48 3.1k
Tiago Torres Portugal 31 1.5k 1.1× 1.4k 1.6× 314 0.7× 488 1.4× 377 1.2× 179 2.8k
Sascha Gerdes Germany 30 1.9k 1.3× 1.2k 1.3× 315 0.7× 346 1.0× 301 1.0× 116 2.5k
Caitriona Ryan United States 28 2.2k 1.6× 1.3k 1.5× 440 1.0× 498 1.4× 404 1.3× 55 3.1k
Michel Le Maître France 24 2.0k 1.4× 1.2k 1.3× 290 0.7× 703 2.0× 182 0.6× 43 2.6k
Sergio Chimenti Italy 23 1.2k 0.9× 896 1.0× 278 0.7× 268 0.7× 142 0.5× 53 1.7k
B K Bang South Korea 17 448 0.3× 520 0.6× 149 0.4× 102 0.3× 186 0.6× 52 1.2k
Charlotte Read United States 7 1.1k 0.8× 635 0.7× 129 0.3× 141 0.4× 164 0.5× 21 1.6k
Marco Galluzzo Italy 22 1.0k 0.7× 720 0.8× 207 0.5× 212 0.6× 305 1.0× 86 1.4k

Countries citing papers authored by Robert M. Day

Since Specialization
Citations

This map shows the geographic impact of Robert M. Day's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert M. Day with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert M. Day more than expected).

Fields of papers citing papers by Robert M. Day

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert M. Day. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert M. Day. The network helps show where Robert M. Day may publish in the future.

Co-authorship network of co-authors of Robert M. Day

This figure shows the co-authorship network connecting the top 25 collaborators of Robert M. Day. A scholar is included among the top collaborators of Robert M. Day based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert M. Day. Robert M. Day is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Crowley, Jeffrey, Diamant Thaçi, P. Joly, et al.. (2017). Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). Journal of the American Academy of Dermatology. 77(2). 310–317.e1. 126 indexed citations
2.
Sobell, Jeffrey M., Dániel Tóth, Ulrich Mrowietz, et al.. (2016). Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis. Acta Dermato Venereologica. 96(4). 514–520. 51 indexed citations
3.
4.
Reich, Kristian, Melinda Gooderham, Anthony Bewley, et al.. (2016). The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE). Journal of the European Academy of Dermatology and Venereology. 31(3). 507–517. 144 indexed citations
5.
Reich, Kristian, Jennifer Soung, Melinda Gooderham, et al.. (2016). THU0439 52-Week Efficacy and Safety of Apremilast and Switch from Etanercept in Patients with Moderate To Severe Psoriasis: Results from The Liberate Study. Annals of the Rheumatic Diseases. 75. 349–349. 2 indexed citations
6.
Thaçi, Diamant, Gil Yosipovitch, Kim Papp, et al.. (2015). Effects of apremilast on pruritus in patients with moderate to severe plaque psoriasis : results from the ESTEEM 1 and 2 trials. Ghent University Academic Bibliography (Ghent University). 1 indexed citations
7.
Rich, Phoebe, Melinda Gooderham, H. Bachelez, et al.. (2015). Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). Journal of the American Academy of Dermatology. 74(1). 134–142. 125 indexed citations
8.
Papp, Kim, Kristian Reich, Craig L. Leonardi, et al.. (2015). Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). Journal of the American Academy of Dermatology. 73(1). 37–49. 483 indexed citations breakdown →
9.
Gottlieb, Alice B., Robert Matheson, Alan Menter, et al.. (2013). Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.. PubMed. 12(8). 888–97. 65 indexed citations
10.
Papp, Kim, Jennifer Clay Cather, Howard Sofen, et al.. (2012). Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. The Lancet. 380(9843). 738–746. 217 indexed citations
11.
Tjandrarini, Dwi Hapsari, Robert M. Day, Chaerul Basri, et al.. (2007). Three-fold reduction in the prevalence of tuberculosis over 25 years in Indonesia.. PubMed. 11(4). 398–404. 30 indexed citations
12.
Gordon, Kenneth B., John Koo, Steven R. Feldman, et al.. (2002). Definitions of Measures of Effect Duration for Psoriasis Treatments. 8a(3). 1–5. 11 indexed citations
13.
Krueger, Gerald G., Steven R. Feldman, Charles Camisa, et al.. (2000). Two considerations for patients with psoriasis and their clinicians:. Journal of the American Academy of Dermatology. 43(2). 281–285. 176 indexed citations
14.
Baughman, Richard D., Robert M. Day, P. Donald Forbes, et al.. (1998). Consensus Workshop on the Toxic Effects of Long-term PUVA Therapy. Archives of Dermatology. 134(5). 595–8. 100 indexed citations
15.
Olsen, Elise A., David L. Cram, Charles N. Ellis, et al.. (1991). A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. Journal of the American Academy of Dermatology. 24(3). 443–447. 67 indexed citations
16.
Millikan, Larry E., Wesley K. Galen, Lee T. Nesbitt, et al.. (1988). Naftifine cream 1% versus econazole cream 1% in the treatment of tinea cruris and tinea corporis. Journal of the American Academy of Dermatology. 18(1). 52–56. 31 indexed citations
17.
Day, Robert M.. (1979). Extraocular Muscle Problems Associated With Graves' Disease: Clinical Evaluation and Diagnosis. Ophthalmology. 86(12). 2051–2052. 5 indexed citations
18.
Day, Robert M.. (1968). Corticosteroids in the Treatment of Optic Nerve Involvement. Archives of Ophthalmology. 79(3). 279–279. 69 indexed citations
19.
Day, Robert M.. (1957). Artificial corneal implants.. Europe PMC (PubMed Central). 55. 455–75. 8 indexed citations
20.
Day, Robert M. & S. C. Werner. (1954). REMOVAL RATE OF RADIOSODIUM (Na24) FROM HUMAN ORBIT IN GRAVES'S DISEASE AND IN HEALTH. Archives of Ophthalmology. 52(1). 85–90. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jennifer Clay Cather Breakdown of academic impact, for papers by Peter van de Kerkhof Breakdown of academic impact, for papers by Tiago Torres Breakdown of academic impact, for papers by Sascha Gerdes Breakdown of academic impact, for papers by Caitriona Ryan Breakdown of academic impact, for papers by Michel Le Maître Breakdown of academic impact, for papers by Sergio Chimenti Breakdown of academic impact, for papers by B K Bang Breakdown of academic impact, for papers by Charlotte Read Breakdown of academic impact, for papers by Marco Galluzzo
Rankless by CCL
2026